Effects of once-yearly injected zoledronic acid hydrate on bone mineral density in patients with primary osteoporosis after daily teriparatide treatment
- Conditions
- Primary osteoporosis
- Registration Number
- JPRN-UMIN000025865
- Lead Sponsor
- Ainomemorial hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Female
- Target Recruitment
- 45
Not provided
1)Anaphylaxis or any history of hypersensitivity to zoledronic acid and other kinds of bisphosnate 2)Serious renal dysfunction: creatinine clearance< 35ml/min 3) Serious heart disease, serious liver dysfunction, diabetes mellitus 4)Endocrine and metabolic disaease which may affect to the bone metabolism, and secondary osteoporosis(e.g. glucocorticoide-induced osteoporosis, rheumatoid arthiritis, immobilization osteoporosis) 5) Patients treated with medication which affect to the bone metabolism as follows, i)Glucocorticosteroids(more than 5mg for over 3 months) except inhaler or nasal drugs ii) Anticancer drugs 6) Patient of the hypocalcemia 7) A pregnant woman or the woman who might be pregnant 8)Patients who was diagnosed all of the L2, L3 and L4 vertebral fractures before zolendronate injection 9)Ptients who were jugged to be inadequate for this study by investigators
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method